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Abstract
Deregulated expression of activin A is reported in several tumors, but its biological functions
in oral squamous cell carcinoma (OSCC) are unknown. Here, we investigate whether acti-
vin A can play a causal role in OSCCs. Activin A expression was assessed by qPCR and
immunohistochemistry in OSCC tissues. Low activin A-expressing cells were treated with
recombinant activin A and assessed for apoptosis, proliferation, adhesion, migration, inva-
sion and epithelial-mesenchymal transition (EMT). Those phenotypes were also evaluated
in high activin A-expressing cells treated with follistatin (an activin A antagonist) or stably
expressing shRNA targeting activin A. Transfections of microRNA mimics were performed
to determine whether the overexpression of activin A is regulated by miR-143/miR-145 clus-
ter. Activin A was overexpressed in OSCCs in comparison with normal oral mucosa, and
high activin A levels were significantly associated with lymph node metastasis, tumor differ-
entiation and poor survival. High activin A levels promoted multiple properties associated
with malignant transformation, including decreased apoptosis and increased proliferation,
migration, invasion and EMT. Both miR-143 and miR-145 were markedly downregulated in
OSCC cell lines and in clinical specimens, and inversely correlated to activin A levels.
Forced expression of miR-143 and miR-145 in OSCC cells significantly decreased the
expression of activin A. Overexpression of activin A in OSCCs, which is controlled by down-
regulation of miR-143/miR-145 cluster, regulates apoptosis, proliferation and invasiveness,
and it is clinically correlated with lymph node metastasis and poor survival.
PLOS ONE | DOI:10.1371/journal.pone.0136599 August 28, 2015 1 / 22
OPEN ACCESS
Citation: Bufalino A, Cervigne NK, de Oliveira CE,
Fonseca FP, Rodrigues PC, Macedo CCS, et al.
(2015) Low miR-143/miR-145 Cluster Levels Induce
Activin A Overexpression in Oral Squamous Cell
Carcinomas, Which Contributes to Poor Prognosis.
PLoS ONE 10(8): e0136599. doi:10.1371/journal.
pone.0136599
Editor: Xin-Yuan Guan, The University of Hong
Kong, CHINA
Received: May 13, 2015
Accepted: August 6, 2015
Published: August 28, 2015
Copyright: © 2015 Bufalino et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by grants from
Fundação de Amparo a Pesquisa do Estado de São
Paulo-FAPESP, São Paulo, Brazil (2010/52547-1,
2011/00691-7 and 2013/01607-6); Conselho Nacional
de Desenvolvimento Científico e Tecnológico-CNPq,
Brasília, Brazil (302464/2011-5 and 473825/2013-9);
and Coordenação de Aperfeiçoamento de Pessoal
de Nível Superior-CAPES, Brasília, Brazil (AUXPE-
PVES-570/2013).
Introduction
Oral cavity cancers represent 6% of all diagnosed cancers worldwide, and oral squamous cell
carcinoma (OSCC) is the most frequent, accounting for 90% of all cases at this site [1]. Despite
continued improvements in the therapeutic strategies, mortality rates of OSCC continue to be
high, giving rise to an overall 5-year survival rate of approximately 50% [1]. This low survival
rate is due to an association of factors, including diagnosis at advanced-disease stage, high
recurrence rates and our incomplete understanding of the molecular mechanisms responsible
for oral tumorigenesis. Thus, elucidating the cellular and molecular mechanisms behind OSCC
is mandatory for a better understanding of the genetic events associated with OSCC progres-
sion and to develop novel and individualized therapeutic approaches to this disease, which
should ultimately provide an important impact on patient survival.
Activin A, the homodimeric protein encoded by the INHBA gene, is a multifunctional
member of the transforming growth factor β (TGF-β) family with important roles in cell
growth, differentiation and apoptosis in events related to angiogenesis, inflammation, immu-
nity and embryogenesis [2]. As a result, defects in its expression have been linked to uncon-
trolled proliferation and survival, leading to cancer development and progression. Although
deregulated expression of activin A has been broadly reported in a variety of cancers [3–5], its
role in OSCCs is not yet well understood. In a recent study our group demonstrated that
immunodetection of activin A correlates with occult lymph node metastasis in patients with
early OSCCs of the tongue and that its expression is an independent marker of patient out-
come, supporting a role of activin A as a prognostic marker of OSCCs [6]. Additionally, we
showed that carcinoma-associated fibroblasts (CAFs) promote tumorigenesis of OSCC cell
lines via secretion of activin A [7]. Furthermore, overexpression of activin A in OSCCs was
associated with increased regional lymph node metastasis and lower patient survival [8].
In this study we confirm the prognostic significance of activin A overexpression in OSCCs
and examine the molecular mechanism by which activin A influences oral tumorigenesis. We
show that activin A overexpression in OSCCs is significantly correlated with regional lymph
node metastasis and poorly differentiated tumors, and patients with high expression of activin
A show shortened survival. In vitro analysis revealed that activin A blocks apoptosis whereas it
controls proliferation via regulation of p16, p21 and p27. Our data also demonstrate that acti-
vin A promotes motility and invasiveness of OSCC cells, as well as epithelial-mesenchymal
transition (EMT), as revealed by modulation of the expression of EMT markers E-cadherin, N-
cadherin and vimentin. Finally, we showed that expression of the miR-143/miR-145 cluster is
inversely correlated with INHBA levels in OSCC cell lines and specimens, and overexpression
of those microRNAs downregulated INHBA mRNA.
Materials and Methods
INHBA mRNA levels in previously published microarrays
To examine the expression pattern of INHBA in published microarray data, we performed a
metanalysis using data mining from the Oncomine Research Premium Edition database
(https://www.oncomine.org). The first step was to identify previously published microarray
gene expression data comparing normal oral mucosa and OSCC. Filters for selection of the
data were studies that included INHBA in the analysis, comparing cancer vs normal tissue,
cancer type (squamous cell carcinoma) and primary tumor sites in the oral cavity. After apply-
ing those filters, we ended up with 9 datasets (312 samples) from published studies. The expres-
sion level was considered the median rank for the gene across each of the analysis, and the
given p-value was based in the median-ranked analysis at a cut off 0.01 (p<0.01).
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Samples and clinicopathological data
To confirm the overexpression of activin A in OSCCs, fresh samples of OSCC (n = 17) and
normal oral mucosa (n = 11) were used to investigate the expression of INHBA using quantita-
tive PCR (qPCR). Those samples were also used for the expression of the putative microRNA
regulators of INHBA mRNA (see below). The samples were snap frozen in liquid nitrogen and
kept at -80°C until use. The initial diagnosis was based on clinical findings and confirmed later
by histopathological analysis of the specimens.
Using immunohistochemistry analysis, we also investigated the association of activin A
expression with clinicopathological features of 115 OSCCs, which were obtained from patients
treated at the Department of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo
Cancer Center, São Paulo, Brazil. The OSCC patients (92 males and 23 females) showed a
mean of 55.6 ± 10.4 years (ranged 31–79 years). History of alcohol consumption was recorded
in 91 patients (79.1%) and tobacco smoking in 106 (92.2%) patients. The site of the primary
tumor was predominantly the tongue (n = 82) and other sites such as the floor of mouth
(n = 10), gingiva (n = 10), buccal mucosa (n = 8) and the retromolar region (n = 5) accounted
for the remaining cases. The patients were staged according to the International Union Against
Cancer (TNM stage) as follows: T1 (n = 10), T2 (n = 31), T3 (n = 31) and T4 (n = 43), as well
as N0 (n = 50) and N+ (n = 65). All patients were staged as M0 at the time of diagnosis. Regard-
ing treatment, surgery as monotherapy was performed in 35 patients, 72 were treated by com-
bination of surgery and postoperative radiotherapy, and 8 patients were treated by surgery and
postoperative radiotherapy and chemotherapy. Tumors were histopathologically classified
according to the World Health Organization (WHO) grading system, and demonstrated a dis-
tribution of 17 well differentiated, 42 moderately differentiated and 56 poorly differentiated
tumors. Surgical margin, identified as the closest distance between the tumor and the surgical
resection edge (both in deep muscle and lateral on mucosa), was categorized into 2 groups
based on cut-off value of 5 mm. Margins of less than 5 mm were considered involved (n = 14),
and margins of 5 mm or more were classified as free (n = 101). Vascular and perineural inva-
sions were categorized as present or absent. After treatment, patients were followed up for at
least 5 years and disease recurrence was histologically confirmed. The outcomes were catego-
rized as overall survival, time from treatment initiation until death or last follow-up informa-
tion, and disease-free survival, time from treatment initiation until diagnosis of the first
recurrence (local, regional or distant) or last follow up information for those without recur-
rence. Patients had signed an informed consent form prior to participation in this study, which
was approved by the Human Research Ethics Committee of the School of Dentistry, University
of Campinas, Brazil (protocol number 031/2011).
Cell culture
HaCat, an immortalized but not transformed epithelial cell line, was maintained in DMEM
(Invitrogen, USA) containing 10% fetal bovine serum (FBS) and antibiotics at 37°C in a 5%
CO2 air atmosphere. Normal human gingival keratinocyte (HGK) cell line was cultured in
serum-free, low calcium medium (Gibco’s Keratinocyte-SFM; Invitrogen, USA) containing
specific supplements and antibiotics in a humidified atmosphere of 5% CO2. The human
OSCC cell lines SCC-4, SCC-9, SCC-15 and SCC-25 were obtained from American Type Cul-
ture Collection (ATCC, Manassas, VA, USA), and cultured as recommended in a 1:1 mixture
of Dulbecco’s modified Eagle’s medium and Ham’s F12 medium (DMEM/F12; Invitrogen,
USA) supplemented with 10% fetal bovine serum (FBS), 400 ng/ml hydrocortisone (Sigma-
Aldrich, USA) and antibiotics. The SCC-9 ZsGreen LN-1 cell line, isolated from a metastatic
cervical lymph node, was previously described [9] and cultured in the same conditions as the
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parental cell line. HSC-3, a human squamous cell carcinoma cell line of the tongue (JCRB
0623; Osaka National Institute of Health Sciences, Japan), was cultured in DMEM/F-12
medium (Invitrogen, USA) supplemented with 10% FBS, 50 μg/ml ascorbic acid (Sigma-
Aldrich, USA), 400 ng/ml hydrocortisone (Sigma-Aldrich, USA) and antibiotics.
qPCR
Total RNA from fresh tissues and cell lines was isolated with the RNeasy mini kit (Qiagen,
USA) or the mirVana miRNA isolation kit (Ambion, USA), according to the manufacturer's
protocols. Following DNase I treatment in order to eliminate genomic DNA contamination,
1 μg of total RNA per sample was used to generate cDNA using Oligo-dT (Invitrogen, USA)
and reverse transcriptase (Superscript II RT enzyme, Invitrogen, USA). The resulting cDNAs
were subjected to qPCR using specific primers and SYBR Green PCR master mix (Applied Bio-
systems, USA) in the StepOnePlus Real Time PCR (Applied Biosystems, USA). Gene expres-
sion was determined using the delta-delta CT method and the housekeeping gene PPIA
(cyclophilin A) was used as reference gene for data normalization. All reactions were per-
formed in triplicate. Pairs of primers are described in S1 Table.
Immunohistochemistry
Activin A immunostaining was performed using the streptavidin-biotin peroxidase complex
method. Briefly, after dewaxing and hydration in graded alcohol solutions, the sections were
treated with 3% H2O2 followed by antigen retrieval with 10 mM citric acid pH 6.0 in a pressure
cooker. After washing with phosphate-buffered saline (PBS), the sections were treated with 1%
bovine serum albumin (BSA) in PBS for 1 h and then incubated with polyclonal rabbit anti-
body against activin A (R&D Systems, USA), diluted 1:100, followed by the LSAB method
(LSAB+ System-HRP kit, Dako, USA). Reactions were developed by incubating the sections
with 0.6 mg/ml 3,3'-diaminobenzidine tetrahydrochloride (Sigma-Aldrich, USA) containing
0.01% H2O2. Control reactions were performed by omission of the primary antibody.
Activin A expression was assessed with the aid of the Aperio ScanScope CS (Aperio Tech-
nologies, USA). Briefly, glass slides were scanned into high-resolution images, which were ana-
lyzed in the Pixel Count V9 algorithm software (Aperio Technologies, USA). The tumor cell
islands were delimitated and by using specific input parameters (hue value = 0.01, hue
width = 0.49, color saturation threshold = 0.025 and intensity threshold ranging from 100 to
205), the percentage of cytoplasm positivity was calculated and classified in three range catego-
ries, according to its staining intensity as weak (from 175 to 205), moderate (from 101 to 174)
and strong (from 0 to 100). To each category, an intensity score was set: 1 for weak, 2 for mod-
erate, and 3 for strong staining. Tumor final scores were calculated as the sum of the percentage
of each category multiplied by its intensity score, using the following equation: [(%weak x 1) +
(%moderate x 2) + (%strong x 3)].
Treatments
Lyophilized recombinant activin A and follistatin (R&D Systems, USA) were dissolved in cul-
ture medium, aliquoted and stored at -80°C. To assess the effect of activin A, cells were cultured
in 0.1% FBS media containing 0, 1, 10 or 100 ng/ml for 24 h. Follistatin was used at concentra-
tion of 100 ng/ml.
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Stable cells mediating INHBA silence
SCC-9 ZsGreen LN-1 cells grown in a 12-well plate at confluence of 50% were incubated with
control or INHBA shRNA lentiviral particles (MISSION shRNA Lentiviral Transduction Parti-
cles, Sigma-Aldrich, USA) in culture media containing 8 μg/ml of polybrene (Sigma-Aldrich,
USA) for 8 h. After washing with PBS, cells were cultured in fresh media for an additional
period of 48 h. Cells were then split in a 1:5 concentration, and cultured for 10 days in the pres-
ence of 1 μg/ml of puromycin dihydrochloride (Sigma-Aldrich, USA) to select resistant cells.
The efficacy of INHBA knockdown was determined by qPCR and enzyme-linked immunosor-
bent assay (ELISA).
ELISA
Conditioned cell culture media was collected and the cells harvested using 0.25% trypsin and
counted with a cell counter (Countess Automated Cell Counter, Invitrogen, USA). After centri-
fugation, microtiter plate wells were coated with 100 μl of the conditioned-media for 2 h at
room temperature. The wells were then washed 3 times with 400 μl of 1% Tween 20 in PBS and
nonspecific binding sites were blocked with 3% BSA in PBS for 2 h. After washing, monoclonal
mouse antibody anti-activin A (clone 69403, R&D Systems, USA), diluted 1:100 in PBS, was
added to the wells and incubated for 2 h. After another washing step, peroxidase-conjugated
anti-mouse IgG (Vector Labs, USA) diluted 1:1000 in PBS was added and maintained for 1 h.
The reaction was developed with 0.5 mg/ml of o-phenylenediamine (Sigma-Aldrich, USA) in
0.5 M citric buffer pH 5.5 containing 0.01% H2O2 for 20 min. After terminating the reaction
with 50 μl of 2 N H2SO4, absorbance was read at 450 nm with λ correction at 570 nm. Activin
A levels, as represented by absorbance values, were calculated by dividing these values by the
number of cells/well.
Apoptosis analysis
The apoptosis index was determined by annexin V labeling. Briefly, cells were harvested,
washed and resuspended in the binding buffer (10 mMHEPES pH 7.4, 150 mMNaCl, 5 mM
KCl, 1 mMMgCl2 and 1.8 mM CaCl2) containing annexin V-PE and 7-AAD (BD Biosciences,
USA). Apoptosis was analyzed on a FACScalibur flow cytometer equipped with an argon laser
(BD Biosciences, USA) and quantified as the number of annexin V-PE positive and 7-AAD
negative cells divided by the total number of cells. A minimum of 10,000 events was analyzed
for each sample.
To confirm the inhibitory effects of activin A, in a second set of experiments, apoptosis was
induced with 0.03 μM staurosporine (Invitrogen, USA) during the last 4 h of activin A treat-
ment, following annexin V labeling.
Bromodeoxyuridine-labeling (BrdU) index
Cells were plated in 96-well plates at a density of 10,000 cells per well in 100 μl of media con-
taining 10% FBS. After 16 h, the cells were washed with PBS and cultured in serum-free media
for an additional 24 h. Following serum starvation, the media were replaced by media contain-
ing 10% FBS. Proliferation rates were determined 24 h after incubation by measuring BrdU
incorporation into DNA using the cell proliferation ELISA BrdU (colorimetric) kit (Roche
Applied Science, USA).
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Cell cycle analysis
Cells were synchronized for 24 h by serum starvation and released with media containing 10%
FBS. After 24 h, cells were collected, fixed in 70% ethanol for 30 min, treated with 10 μg/ml of
RNAse (Sigma-Aldrich, USA) and stained with 50 μg/ml of propidium iodide (Sigma-Aldrich,
USA). The distribution of cells in the cell cycle phases was analyzed with the aid of the FACS-
Calibur flow cytometer (BD Biosciences, USA) equipped with an argon laser and the ModFit
LT software (Verity Software House, USA).
Western blot
Western blot analysis was used to determine the expression of proteins related to G1 phase of
the cell cycle, and also to confirm the effects of activin A on EMT markers. Cells were washed
with cold PBS and lysed in a buffer containing 20 mM Tris-HCl pH 8.0, 137 mMNaCl, 10%
glycerol, 2 mM EDTA, and protease inhibitors. After centrifugation, protein concentrations
were measured using a protein assay according to the manufacturer’s instructions (Bio-Rad
Protein Assay, Bio-Rad, USA). Thirty μg of total proteins per sample were resolved in a 10%
SDS-PAGE under reducing conditions, and transferred to nitrocellulose membranes. The
membranes were blocked with 10% non-fat dry milk in PBS containing 0.1% Tween-20, rinsed
in the same buffer, and incubated for 2 h with the primary antibodies (S2 Table). After wash-
ing, the protein bands were detected using enhanced chemiluminescence (ECL) Western Blot-
ting System (GE Healthcare, USA).
Adhesion assay
Wells of a 96-well culture plate were coated with 10 μg/cm2 of type I collagen, fibronectin or
laminin (BD Biosciences, USA) in 100 μl of PBS for 24 h at 4°C. The wells were washed 3 times
with 200 μl of PBS and then coated with the same volume of 3% BSA in PBS for 2 h at 37°C.
Control wells were coated only with 3% BSA solution. Cells were harvested and then resus-
pended in DMEM supplemented with 3% BSA at a final concentration of 3,000 cells in 100 μl.
The wells were washed and 100 μl of the cell suspension was added to each well. The plate was
incubated for 1 h at 37°C in 5% CO2. Non-adherent cells were washed away and remaining
adhered cells were fixed with 10% formalin for 15 min and stained with 1% toluidine blue in
1% borax solution. Absorbance was measured at 650 nm.
Hanging drop assay
Hanging drop assay was performed to estimate the cell-cell adhesive properties of activin A-
silenced cells, as described previously with few modifications [10]. Briefly, 2x104 cells were sus-
pended in 27 μl drops of complete media and kept in the lid of 35 mm plate for 16 h at 37°C in
a 5% CO2 air atmosphere. Images of cell aggregates of 5 random fields from 5 different suspen-
sions were visualized with a confocal microscopy in sequential Z-stack images (LEICA TCS
SP5, Leica Microsystems, Germany).
Migration and invasion assays
Transwell migration and invasion assays were performed in 6.5 mm inserts with 8 μm pore
size (Corning, USA). For invasion assay, membranes were coated with 50 μl of growth factor-
reduced matrigel (BD Biosciences, USA). Serum starved cells (80,000 cells/well) were plated
into the upper chamber in 200 μl of serum-free DMEM. As chemoattractant, 500 μl of com-
plete medium was used in the lower chamber. Experiment times varied between 24 h for migra-
tion assays and 72 h for invasion assays. Assessment of migration or invasion was performed
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by gently removing cell in the interior part of the insert with a cotton swab. Cells on the bottom
of the membrane were fixed in 10% formalin for 15 min and stained with 1% toluidine blue in
1% borax solution. The excess dye was washed out and cells were then eluted in 1% SDS solu-
tion for 5 min. Absorbance was measured at 650 nm.
Quantification of filopodia and lamellipodia
Cells grown in cell culture glass slides (Lab-Tek, Thermo Scientific, USA) were fixed in 4%
paraformaldehyde in PBS for 10 mim and then permeabilized with 0.5% Triton X-100 in PBS
for 10 min. Following, cells were incubated with Alexa Fluor 488 phalloidin (diluted 1:200,
Invitrogen, USA) and DRAQ5 (diluted 1:1000, BioStatus Limited, United Kingdon) for 1 h.
Quantification of filopodia and lamellipodia was performed with images captured with a con-
focal microscopy (LEICA TCS SP5, Leica Microsystems, Germany).
miR-143 and miR-145 expression analysis
The expression of miR-143 and miR-145 was assessed in cell lines and fresh tumor specimens.
Briefly, 1 μg of total RNA was converted into specific cDNA derived from mature microRNAs
using TaqMan microRNA Reverse Transcription Kit (Applied Biosystems, USA) and quanti-
fied in triplicate using the TaqMan microRNA assay. The small nucleolar RNA (snoRNA)
RNU48 was used as endogenous control. All assays were obtained from Applied Biosystems
through their Assay-on-Demand service. Data were quantified and analyzed using sequence
detection system (version 2.3) (Applied Biosystems, USA). The microRNA relative expression
in fresh tumor specimens was normalized against endogenous control and pooled normal oral
mucosa samples, and in the cell lines against endogenous control and HGK cells [11].
Effect of miR-143 and miR-145 mimics on INHBA expression
SCC-9 and SCC-9 ZsGreen LN-1 cells were transfected with miR-143 or miR-145 mimics
using the RNAiMAX reagent (Invitrogen, USA) as per the manufacturer's instructions. As con-
trol, cells were transfected with an unspecific scramble sequence (Pre-miR Negative Control
#1, Life Technologies, USA). After 72 h, cells were harvested and subjected to qPCR and ELISA
for quantification of INHBA as described above.
Statistical analysis
Differences on expression of INHBA between fresh OSCC and normal oral mucosa samples
were analyzed using the Mann-Whitney U test. Correlations between immunohistochemical
expression of activin A and clinicopathological parameters of the tumors were performed
using Spearman’s rank correlation. Survival curves were constructed based on the Kaplan-
Meier method and compared with the Log-rank test. For multivariate survival analysis,
the Cox proportional hazard model with a stepwise method including all parameters was
employed.
All in vitro assays were performed at least three times in triplicates or quadruplicates. For
those assays, Mann-Whitney U test or one-way analysis of variance (ANOVA) with post-hoc
comparisons based on the Tukey's multiple comparisons test were applied. The level of signifi-
cance considered was 5% (p0.05).
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Results
INHBA is overexpressed in OSCCs compared to normal oral mucosa
To evaluate the expression of activin A in OSCCs, we first performed a metanalysis with pub-
lished microarray data compiled from Oncomine Research Premium Edition database. Com-
parison across microarray gene expression studies showed that INHBA mRNA is significantly
overexpressed in OSCC samples compared with normal oral mucosa (p = 0.0005). In line with
this observation, we also detected a significantly higher content of INHBA mRNA in fresh
OSCCs in comparison to normal control tissues (p = 0.0001; Fig 1). In this specific analysis, we
used a pool of 11 normal oral tissues as a reference. Sixteen out of 17 OSCC samples showed, at
least, 2-fold increased INHBA mRNA levels compared to the reference pool. Based on those
results, we next analyzed the biological effects of activin A in OSCCs.
Overexpression of activin A is significantly associated with shortened
survival
To investigate whether activin A expression is associated with clinicopathological features of
OSCC patients, we performed immunohistochemistry in 115 human OSCCs. Activin A was
observed as a cytoplasmatic stain with variable distribution and intensity in the tumor cells
(Fig 2). Immunoreactivity was also found in stromal cells, including inflammatory cells, CAFs
and endothelial cells. The clinicopathological correlations with the expression of activin A in
the tumor cells are described in Table 1. A significant correlation between activin A expression
in the tumor cells and cervical lymph node metastasis (N stage) was observed, in that patients
with metastasis (N+) had significantly higher activin A expression (p = 0.02). A significant cor-
relation between high activin A expression and histopathological grade of the tumors was also
found (p = 0.03). Approximately 60% of the tumors classified as poorly differentiated demon-
strated high levels of activin A, while only 29% of the well differentiated tumors showed high
activin A levels.
High activin A immunoreactivity was a marker of reduced overall survival with a 5-year sur-
vival of 53.8% (95% CI 46.9–60.7) for the patients with strong positivity for activin A compared
with 67.9% (95% CI 61.8–74.1) for those with low activin A expression (p = 0.01; Fig 3A). No
significant influence of activin A immunoexpression in relapse (disease-free survival) was
observed in this cohort (Fig 3B). To assess the independent predictive value of activin A, multi-
variate Cox-regression analysis of overall survival related to its expression levels in combina-
tion with other clinicopathological parameters was performed (Table 2). This analysis revealed
that activin A and vascular infiltration were independent prognostic factors of this OSCC
cohort. For activin A, a hazard ratio (HR) of 2.59 (95% CI 1.57–4.28, p = 0.0002) was found for
high activin A immunopositivity in reference to low activin A levels. Similarly, presence of vas-
cular infiltration revealed a HR of 1.94 (95% CI 1.18–3.21, p = 0.001).
High levels of activin A suppresses apoptosis
To better understand the role of activin A in the events that control oral tumorigenesis, HaCat
cells, which showed the lowest expression of activin A (S1 Fig), were treated with different con-
centrations of activin A (1, 10 and 100 ng/ml) for 24 h. In order to support the specific findings,
two approaches were realized: treatment with 100 ng/ml of follistatin, an antagonist of activin
A, and mRNA silencing using interference RNA. For both approaches, SCC-9 ZsGreen LN-1
cells, which showed the highest activin A expression levels (S1 Fig), were selected. SCC-9
ZsGreen LN-1 cells transducted with lentivirus carrying a specific sequence against INHBA
Activin A Overexpression in Oral Cancer
PLOS ONE | DOI:10.1371/journal.pone.0136599 August 28, 2015 8 / 22
demonstrated a significant reduction in both mRNA and protein levels in comparison with
cells transducted with the control-sequence (S2 Fig).
Compared with untreated cells, activin A blocked apoptosis in a concentration-dependent
manner (Fig 4A). The decrease in the amount of apoptotic cells was first significant at concen-
tration of 10 ng/ml of activin A and remained so at 100 ng/ml. To confirm this protective effect,
HaCat cells under 24 h treatment with activin A were exposed to 0.03 μM of staurosporine, an
inductor of apoptosis, in the last 4 h of treatment. Activin A was able to reduce significantly
the number of apoptotic cells in a dose-dependent manner, reaching the maximum reduction
(approximately 2/3) at concentration of 100 ng/ml (Fig 4B). Conversely, the number of apopto-
tic cells was significantly increased after 24 h treatment of SCC-9 ZsGreen LN-1 cells with fol-
listatin (Fig 4C). Similarly, knock down of activin A promoted apoptosis in SCC-9 ZsGreen
LN-1 cells, which was partially rescued with 100 ng/ml activin A (Fig 4D).
Activin A promotes proliferation via regulation of cyclin-dependent
kinase (CDK) inhibitors
Although no significant effects on proliferation, as evaluated by BrdU and cell cycle analysis,
were observed after activin A treatment of HaCat cells (Fig 5A and 5B), follistatin reduced
significantly the proliferation of SCC-9 ZsGreen LN-1 cells (Fig 5C and 5D). The difference
between follistatin-treated and untreated cells was small, but statistically significant (p<0.01,
Fig 1. Activin A is overexpressed in OSCCs. The levels of INHBAmRNA in 17 fresh samples of OSCC and 11 normal oral mucosa samples were
assessed by real-time PCR. Expression was normalized to the average value of the normal oral tissues. Data showed a clear overexpression above 2-fold in
16 out of 17 OSCC specimens (p = 0.0001).
doi:10.1371/journal.pone.0136599.g001
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Fig 5C). The specific shRNA against activin A drastically reduced the proliferation of SCC-9
ZsGreen LN-1 cells (p<0.001, Fig 5E). Accordingly, activin A downregulation promoted a sig-
nificant increase of the number of cells at G0–G1 phases (p<0.001) and a clear reduction at S
phase (p<0.01) in comparison with control (Fig 5F).
Fig 2. Activin A immunodetection in OSCC. (A) Positivity for activin A was observed in the cytoplasm of the tumor cells and in few stromal cells adjacent
the tumor. (B) High power view revealed that tumor cells demonstrate variable expression of activin A even in the same tumor. (original magnification: A x100
and B x200).
doi:10.1371/journal.pone.0136599.g002
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To further characterize the effects of activin A knock down on cell cycling, protein related
to G1-S transition were analyzed using western blot. As shown in Fig 6, knock down of activin
A was associated with increased expression of CDK inhibitors p16, p21 and p27 and a
decreased phosphorylation of RB. The levels of CDK2, CDK4, CDK6, cyclin D1 and cyclin E
were unaffected.
Overexpression of activin A induces EMT and invasion
In the process of invasion and metastasis, tumor cells loss epithelial features and evoke mesen-
chymal phenotypes characterizing the EMT process. TGF-β and its family members are recog-
nized promoters of EMT [12]. To gain insights into the regulation of EMT and invasion by
activin A, we examined several features such as expression of epithelial marker E-cadherin and
mesenchymal markers N-cadherin and vimentin, adhesive capacity, presence of filopodia and
lamellipodia, motility and invasiveness. Reduced levels of E-cadherin mRNA were observed in
HaCat cells treated with 10 and 100 ng/ml of activin A (Fig 7A). Concomitantly, activin A
increased the expressions of N-cadherin and vimentin mRNA at concentrations 100 ng/ml
(Fig 7A). Conversely, follistatin promoted the expression of E-cadherin mRNA whereas
decreased the expression of N-cadherin and vimentin in SCC-9 ZsGreen LN-1 cells (Fig 7B).
As revealed in Fig 7C, shINHBA target cells showed lower levels of N-cadherin and vimentin
mRNA, and higher E-cadherin mRNA levels compared to shControl cells. The levels of those
EMT markers were also analyzed at protein levels by western blot; similar changes were
observed at the protein level (S3 Fig). In accordance with those results, our observations using
phase contrast microscopy suggested that shINHBA cells have more cell-cell attachment. In
order to confirm such observation, hanging drop assay was performed. Activin A knock down
cells formed larger aggregates compared to control cells, indicating that activin A controls of
cell-cell contacts via regulation of E-cadherin (Fig 7D).
Next, the effects of activin A on adhesive properties of the cells were investigated on
surfaces coated with type I collagen, fibronectin and laminin. In general, activin A significantly
increased the adhesion of HaCat cells on surfaces coated with type I collagen, fibronectin and
laminin (Fig 8A), whereas follistatin reduced adhesion significantly to surfaces coated with
type I and fibronectin (Fig 8B). Adhesion of shINHBA cells was significantly higher than
Table 1. Spearman correlation between activin A immunohistochemical expression and clinicopatho-
logical variables.
Variables Correlation Coefﬁcient p value
Age 0.025 0.79
Gender -0.013 0.89
Ethnic group -0.017 0.85
Smoking habit -0.052 0.58
Drinking habit -0.067 0.47
Tumor site 0.075 0.42
T stage 0.082 0.38
N stage 0.216 0.02
Treatment 0.111 0.23
Histopathological grade 0.207 0.03
Surgical margin status -0.001 0.98
Vascular invasion -0.023 0.81
Perineural invasion 0.037 0.69
Recurrence 0.026 0.77
doi:10.1371/journal.pone.0136599.t001
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shControl cells in all 3 coated-surfaces (Fig 8C). Activin A significantly augmented migration
of HaCat cells (p<0.01, Fig 8D), whereas follistatin significantly inhibited the migration and
invasiveness of SCC-9 ZsGreen LN-1 parental cells (p<0.05, Fig 8E). shINHBA cells showed
significantly lower migration (p<0.01) and invasion (p<0.05) compared with control cells (Fig
8F). The number of filopodia and lamellipodia in shINHBA cells was also significantly lower
compared with shControl cells (p<0.001, Fig 8G and S4 Fig).
Downregulation of miR143/miR145 cluster is associated with INHBA
overexpression in OSCC
Since previous study showed that miR-145 regulates features similar to those regulated by acti-
vin A in OSCCs [13], and to gain insight into the molecular mechanism by which activin A is
overexpressed in OSCCs, we determined the relationship between INHBA mRNA levels and
expression of miR-143 and miR-145 in a series of OSCC cell lines and fresh tumor samples.
For both microRNAs, a significant and inverse correlation with INHBA levels was observed in
the cell lines (rho = -0.75 and p = 0.033 for miR-143, rho = -0.62 and p = 0.042 for miR-145,
Fig 9A) and fresh tumor samples (rho = -0.72 and p = 0.01 for miR-143, rho = -0.70 and
p = 0.02 for miR-145, Fig 9B).
To determine whether miR-143 and miR-145 regulate INHBA mRNA, SCC-9 and SCC-9
ZsGreen LN-1 cells were transfected with miR-143 and miR-145 mimics. Fig 10A shows the
Fig 3. Survival curves based on immunoexpression of activin A. (A) Overall survival, as determined by the period between the treatment beginning until
death or last follow-up information, and (B) disease-free survival, time between initiation of treatment until diagnosis of the recurrence (local, regional or
distant) or last follow up information for those without recurrence. Censored deaths are indicated by vertical lines. The univariate analysis revealed that high
positivity for activin A is significantly associated with shortened overall survival (p = 0.01).
doi:10.1371/journal.pone.0136599.g003
Table 2. Coxmultivariate analysis of factors associated with risk of death.
Parameter Overall survival
HR 95% CI p value
Activin A expression
Low Reference
High 2.59 1.57–4.28 0.0002
Vascular invasion
No Reference
Yes 1.94 1.18–3.21 0.001
doi:10.1371/journal.pone.0136599.t002
Activin A Overexpression in Oral Cancer
PLOS ONE | DOI:10.1371/journal.pone.0136599 August 28, 2015 12 / 22
efficiency of miR-143 and miR-145 transfection in SCC-9 and SCC-9 ZsGreen LN-1 cells,
which reached 5 to 8-fold increased levels. The increase in miR-143 and miR-145 levels
resulted in a concomitant decrease in activin A mRNA and protein, demonstrating that miR-
143/miR-145 cluster regulates INHBA mRNA levels (Fig 10B).
Discussion
Like other members of the TGF-β family, dual functions in cancer, both pro- and anti-tumori-
genesis, have been attributed to activin A depending of the tumor development stage and can-
cer type [14–16]. Furthermore, whilst some studies have demonstrated a stimulation of
apoptosis after activin A treatment [17–18], others showed that activin A can restrain apoptosis
via downregulation of caspase 3 expression [19]. Activin A inhibited cell growth of breast can-
cer cells [20–21] and prostate tumors [22], but it promoted the proliferation of ovarian cancer
cells [23–24]. Most studies, however, have shown that activin A is involved in the progression
of numerous types of human cancers via its oncogenic roles. Activin A promoted migration
and invasiveness of different cancer cells [25–28], which were concomitant with a down-regu-
lation of E-cadherin, a marker of EMT [25–29]. Oral carcinoma cells in culture expressed
Fig 4. Activin A controls apoptosis of OSCC cells. Apoptotic cells were stained with annexin V-PE and propidium iodide and analyzed by flow cytometry.
(A) Activin A blocked apoptosis of HaCat cells, reaching significant levels at concentration of 10 and 100 ng/ml. (B) Activin A reduced significantly apoptosis
induced by staurosporine. Cells were treated with increased concentrations of activin A for 24 h, but in the last 4 h 0.03 μM of staurosporine were added to the
cells. (C) Follistatin significantly induced apoptosis of SCC-9 ZsGreen LN-1 cells. (D) Activin A stable knockdown in SCC-9 ZsGreen LN-1 cells was
significantly associated with increased levels of apoptosis. This phenotype was partially rescued adding 100 ng/ml of activin A. Bars represent the
means ± SD of three independent experiments. *p>0.05, **p>0.01, ***p>0.005.
doi:10.1371/journal.pone.0136599.g004
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activin A and knock down with specific siRNA against INHBA reduced growth and induced
invasion of tumor cells [8]. It was also associated with poor prognosis in OSCCs [8]. Our inter-
est in activin A is based on our recent studies demonstrating that OSCC cell proliferation is
increased in response to high levels of activin A released by CAFs present in the tumor micro-
environment [7], and that expression of activin A by OSCC cells can be useful for prognostica-
tion of OSCC of the tongue, revealing patients with occult lymph node metastasis and lower
Fig 5. Downregulation of activin A leads to a decrease in proliferation. Treatment with recombinant activin A was not able to promote proliferation of
HaCat cells, as revealed by bromodeoxyuridine (BrdU) incorporation index (A) and cell cycle analysis (B). (C) Follistatin at 100 ng/ml significantly blocked
BrdU incorporation in SCC-9 ZsGreen LN-1 cells, but no effects on cell cycle distribution were observed (D). Knockdown of activin A significantly decreased
proliferation (E), enhancing the number of cells at G0/G1 and reducing the number in the S phase of cell cycle (F). Bars represent the means ± SD of three
independent experiments. *p<0.01, **p<0.001, ***p<0.0001.
doi:10.1371/journal.pone.0136599.g005
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Fig 6. Knockdown of activin A increases cyclin-dependent kinase inhibitors p16, p21 and p27.Cells
were harvested, lysed and proteins were subjected to western blot analysis using specific antibodies against
p16, p21, p27, CDK2, CDK4, CDK6, cyclin D1, cyclin E and phospho-RB. β-actin was used as loading
control. A strong increase in expression of p16, p21 and p27, concomitant with decrease in phosphorylation
of RB, was observed in shINHBA cells in comparison with shControl cells. Beta-actin was used as loading
control.
doi:10.1371/journal.pone.0136599.g006
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overall survival [6]. In the current study we further demonstrate that activin A is overexpressed
in OSCCs in comparison with normal oral mucosa, and its expression is correlated with lymph
node metastasis (N+), poor histopathological grade, and patients whose tumors overexpressed
activin A had a worse prognosis, as revealed by shortened overall survival. The present study
also revealed that activin A regulates essential phenotypes associated with malignant transfor-
mation, such as apoptosis, proliferation, adhesion, migration, invasion and EMT process. Fur-
thermore, our data demonstrate that a possible mechanism of activin A mRNA overexpression
in OSCC is downregulation of miR-143/miR-145 cluster. Together, these data support a causal
role for activin A in OSCCs, and suggest that activin A expression might be helpful as a prog-
nostic marker for patients with this disease.
Activin A is known to control proliferation and apoptosis in a number of contexts both in
normal development and tumorigenesis [2]. Since during the expansion and differentiation
of stem cell population activin A increases proliferation and decreases apoptosis [30], it is
Fig 7. Activin A induces epithelial-mesenchymal transition (EMT). Levels of E-cadherin, N-cadherin and vimentin were analyzed by qPCR. (A)
Treatment with activin A decreased the expression of epithelial marker E-cadherin and induced the mesenchymal markers N-cadherin and vimentin in HaCat
cells. (B) Follistatin treatment promoted the expression of E-cadherin and blocked the expression of N-cadherin and vimentin in SCC-9 ZsGreen LN-1 cells.
(C) Abrogation of activin A induced the expression of E-cadherin, whereas downregulated the production of N-cadherin and vimentin. (D) Representative
images of aggregates formed by shControl and shINHBA cells in hanging drop assay. Silencing of activin A induced cell-cell adhesion, as revealed by larger
aggregates in shINHBA cultures compared to those in shControl cultures. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
doi:10.1371/journal.pone.0136599.g007
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expected that deregulation of activin A in adult cells would have dire consequences, such as
cancer development and progression. In prostate cancer, activin A plays a paradoxical role,
because in low-grade tumors, apoptosis is increased by activin A, but in high-grade metastatic
tumors, cells are no longer sensitive to activin A-mediated apoptosis [31]. A significant toler-
ance to Fas-induced apoptosis was also observed in esophageal carcinoma cells overexpressing
activin A [3]. Similarly, the results presented in this study showed that high levels of activin A
suppress apoptosis of OSCC cells, and the treatment of low-activin A expressing cells with acti-
vin A partially inhibited staurosporine-mediate apoptosis. In different cell lines activin A
induces proliferation, which is antagonized by follistatin [8,23,24]. However, the mechanisms
involved in activin A-promote proliferation of OSCC cells are not characterized. Our results
showed that knock down of activin A results in reduction of proliferation and retention of the
cells at G0–G1 phases of cell cycle, which were accompanied by increased levels of p16, p21
and p27, indicating the mechanisms involved in activin A cell growth control.
Inappropriate expression of activin A has been shown to modulate migration and invasion
in different cell lines. Kang et al. [26] demonstrated that activin A promotes migration of pros-
tate cancer cells through SMAD pathway and androgen receptor activation, thereby promoting
Fig 8. Activin Amodulates the adhesion, migration and invasion of OSCC cells. (A) Activin A treatment induced significantly the adhesion of HaCat
cells on surfaces coated with type I collagen, fibronectin or laminin. (B) Follistatin decreased significantly the adhesion of SCC-9 ZsGreen LN-1 cells o
surfaces coated with type I collagen and fibronectin. (C) Activin A knockdown augmented the adhesion to coated-surfaces, as revealed by significantly higher
adhesion of shINHBA cells compared with shControl cells. (D) Activin A induced significantly the migration of HaCat cells, whereas follistatin blocked it and
also reduced significantly the invasion of SCC-9 ZsGreen LN-1 cells through Matrigel-covered surfaces (E). (F) The migration and invasion of shINHBA cells
were significantly lower in comparison with shControl cells. (G) Knock down of activin A interferes with cytoskeleton organization, reducing filopodia and
lamellipodia formation. The number of filopodia and lamellipodia was significantly lower in shINHBA cells than in shControl cells. *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001.
doi:10.1371/journal.pone.0136599.g008
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bone metastasis. In an esophageal organotypic culture model, activin A treatment resulted in
MMP-dependent invasion, requiring the presence of fibroblasts [28]. Furthermore activin A
induced trophoblast cell invasion in parallel with the expression of N-cadherin, SNAIL and
SLUG, however siRNA-mediated depletion of SNAIL or SLUG did not affect activin-induced
N-cadherin expression [32]. Those data in conjunction with recognized functions of TGF-β
family members in the regulation of EMT suggest that activin A may induce migration and
invasion as an end point of EMT process. EMT is the biological process by which epithelial
cells loss the cell-to-cell adhesions, gain the expression of mesenchymal proteins and enhanced
migratory and invasive capacity, allowing tumor cells to acquire metastatic properties [23].
Although EMT is dependent of a series of cellular events, the reduction of E-cadherin expres-
sion in consonance with upregulation of mesenchymal proteins such as N-cadherin and
vimentin have been the most common markers of EMT [33]. In cells depleted of activin A, we
observed an induction of E-cadherin and a repression of N-cadherin and vimentin, in conso-
nance with other EMT-relates features including alterations in the adhesive proprieties to
ECM proteins, diminished cell-cell adhesion, reduced filopodia and lamellipodia formations
and decreased migration and invasion. In support of these in vitro findings, high immunohis-
tochemical expression of activin A was significantly correlated with lymph node metastasis.
Therefore, it is possible that overexpression of activin A evokes the EMT process, an important
phenotype for invasion and metastasis of malignant cells.
Fig 9. Expression of INHBA is inversely correlated with miR-143 andmiR-145 expression in OSCC cells lines and tumor samples. (A) Spearman
correlation analysis between the expressions of INHBA and miR-143 and miR-145 in 7 OSCC cell lines (A) and in 11 OSCC fresh samples (B). A significant
inverse correlation was observed between both miR-143 and miR-145 and INHBA expression levels.
doi:10.1371/journal.pone.0136599.g009
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Although overexpression of activin A has been reported in several cancers, the mechanisms
responsible for this overexpression are unknown. Our findings revealed that miR-143 and
miR-145 are downregulated in OSCC cell lines and specimens, and their expressions are
inversely correlated with INHBA levels. Additionally, we found that the transfection of miR-
143 and miR-145 mimics in OSCC cells result in a downregulation of INHBA, suggesting that
activin A overexpression in OSCCs is, at least in part, regulated by those microRNAs. Increas-
ing evidences indicate that miR-145 and, more recently, miR-143 act a tumor suppressor clus-
ter in numerous human cancers [34–36]. For example, ectopic expression of miR-143
significantly inhibited cell proliferation of non-small cell lung cancer cells [37] and migration
and invasion in prostate cancer [38]. The levels of miR-145 decreased gradually, from normal
to cancer, during breast and prostate cancer progression [39–40]. In addition, a previous study
by Drebber et al. [41] showed that miR-145 downregulation may be an important molecular
biomarker for early diagnosis of colon cancer, and its elevation in tumor tissues is predictive of
good chemoradiotherapy treatment response. Recently, Shao et al. [13] reported that the upre-
gulation of miR-145 resulted in a suppression of oral tumor cell proliferation, migration and
invasion. Interestingly, in silico analysis indicates there are no putative conserved binding sites
for either miR-143 or miR-145 in the 3’UTR of the INHBA transcript (data not shown), sug-
gesting the repression observed here may be subsequent to the down-regulation of a direct
Fig 10. INHBAmRNA is target by miR-143 andmiR-145. (A) SCC-9 and SCC-9 ZsGreen LN-1 cells were exposed to Scramble control or miR-143 and
miR-145 mimics. qPCR analysis demonstrated that levels of miR-143 and miR-145 were dramatically increased after introduction of the mimics. (B) Levels of
activin A mRNA and protein were clearly decreased in both OSCC cell lines, demonstrating that miR-143/miR-145 cluster regulates INHBAmRNA levels.
doi:10.1371/journal.pone.0136599.g010
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target able to regulate activin A expression. Given the importance of miR-143 and miR-145 in
cancer, particularly associated with activin A regulation, further studies shall be conducted to
address their roles in oral carcinogenesis.
In summary, activin A shows pleiotropic functions affecting many cellular processes includ-
ing proliferation, survival and invasion [2]. It has been postulated that deregulation of activin
A leads to an out of context activation of those cellular functions, contributing to tumor initia-
tion and progression. In the present study we show that overexpression of activin A in OSCCs,
which is at least in part caused by downregulation of miR-143/miR-145 cluster, is correlated
with lymph node metastasis and overall survival. Moreover, strong evidences revealed that acti-
vin A overexpression in OSCC cells enhances survival and promotes proliferation, via regula-
tion of CDK inhibitors p16, p21 and p27, and migration and invasion, via promotion of EMT.
Overall, our data suggest that deregulated expression of activin A in oral cells actively promotes
tumorigenesis by control important phenotypes related to malignant transformation.
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